The $50B Patent Problem: How to Protect Drugs That Are Part Biologic, Part Small Molecule
Combination drugs — pairing a biologic with a small molecule — are among the most commercially valuable assets in pharma. […]
The $700B Generic Drug Opportunity Big Pharma Is Still Getting Wrong
The global generic drug market will cross $700 billion by 2032. Most of that growth will not come from the
The $700B Generic Drug Opportunity Big Pharma Is Still Getting Wrong Read Post »
How ANDA Timing Wins Generic Drug Markets: The Complete Patent Strategy Playbook
Generic drugs fill 90% of U.S. prescriptions and capture 18% of revenue. That gap is the whole game. The companies
How ANDA Timing Wins Generic Drug Markets: The Complete Patent Strategy Playbook Read Post »
The $200B Complex Generic Opportunity Big Pharma Is Ignoring
A technical and commercial intelligence guide to complex generic development, patent strategy, regulatory sequencing, and emerging market positioning for pharma
The $200B Complex Generic Opportunity Big Pharma Is Ignoring Read Post »
The $926B Generic Drug Race: How to Win Before the Patent Clock Runs Out
The generic drug industry operates on a paradox that never fully resolves. Generic and biosimilar medicines fill 90% of all
The $926B Generic Drug Race: How to Win Before the Patent Clock Runs Out Read Post »
The $400B Patent Trap: How Hatch-Waxman Built the System Big Pharma Learned to Game
Forty years after Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, the law’s core tension
The $400B Patent Trap: How Hatch-Waxman Built the System Big Pharma Learned to Game Read Post »
The $100B Intelligence Gap: How Pharma’s Most Powerful Competitive Tools Are Being Weaponized in the Orange and Purple Books
The Orange Book and Purple Book are not regulatory housekeeping. They are the official ledgers where billions of dollars of
The $300B Erosion Problem: How Drug Market Share Actually Dies After Patent Expiry
More than $200 billion in pharmaceutical revenue faces patent expiry through 2030, with some analyst projections reaching $300 billion. For
The $300B Erosion Problem: How Drug Market Share Actually Dies After Patent Expiry Read Post »
How Generic Drugs Actually Win Hospital Formularies (And Why Price Alone Keeps Losing)
Generic drugs account for 90% of U.S. prescriptions yet only 17.5% of total drug spending. That math is possible because
How Generic Drugs Actually Win Hospital Formularies (And Why Price Alone Keeps Losing) Read Post »
